Loading
A liposomal formulation locking cytarabine and daunorubicin in a fixed ratio lengthened survival compared with standard 7+3 chemotherapy in patients aged 60 to 75 with secondary or therapy-related acute myeloid leukaemia, and more of them reached transplant.
Phase 3 trial of 309 patients aged 60 to 75 with newly diagnosed high-risk or secondary AML randomised to CPX-351 or conventional cytarabine plus daunorubicin (7+3).
Median overall survival was 9.56 months with CPX-351 against 5.95 months with 7+3 (hazard ratio 0.69); remission rates were higher and outcomes after transplant were better, with a longer recovery of blood counts as the main cost.
CPX-351 is the preferred intensive induction for fit older patients with secondary or therapy-related AML in many centres, mainly as a bridge to allogeneic transplant.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Secondary and therapy-related acute myeloid leukaemia, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.
Shares Daunorubicin, Cytarabine.